綠康生化(002868.SZ):上半年預虧5000萬元-6500萬元
格隆匯7月9日丨綠康生化(002868.SZ)公佈2024年半年度業績預吿,經財務部門初步測算,預計2024年半年度實現歸屬於上市公司股東的淨虧損5,000萬元-6,500萬元,上年同期虧損4,666.52萬元;扣除非經常性損益後的淨虧損8,500萬元-9,800萬元,上年同期虧損6,589.77萬元;基本每股虧損0.32元/股-0.42元/股;營業收入3.6億元-3.8億元,上年同期2.3億元。
公司本期業績變動的主要原因是:1、關於公司光伏膠膜業務方面,相比於去年同期的投資建設,今年上半年已轉為EVA和EPE膠膜的試產、產能爬坡及客户導入階段。此外,今年以來光伏膠膜原材料粒子價格持續下跌,公司對庫存膠膜粒子計提減值。綜合以上因素,光伏膠膜業務相應增加虧損約4,000萬元;2、關於公司獸藥業務方面,因銷售的增長以及產品技術水平的提升,相比於去年同期減少虧損約4,000萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.